Safety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver Resection

Sponsor
West China Hospital
Study ID
NCT07295275
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Laparoscopic Anatomical Liver Resection (guided by transarterial injection of ICG) — PROCEDURE
    Laparoscopic liver resection using ICG fluorescence imaging for tumor and liver segment visualization. Comparison lies in the route of ICG administration (Arterial vs. Portal).

Study Details

This multicenter, ambispective cohort study evaluates the safety and efficacy of trans-arterial Indocyanine Green (ICG) fluorescence-guided laparoscopic liver watershed resection for Hepatocellular Carcinoma (HCC). The study aims to compare the outcomes of the trans-arterial ICG staining approach versus the conventional trans-portal (portal vein) ICG staining approach.

Key Dates

First listed
Dec 19, 2025
Start date
Mar 1, 2026
Status verified
Dec 2025
Primary completion
Jan 1, 2028
Completion
Sep 1, 2028

Study Design

Enrollment
200 participants (estimated)

Arms

  • Arm: Transarterial ICG Group
    Patients who underwent laparoscopic anatomical liver resection guided by superselective transarterial injection of ICG.
  • Arm: Transportal ICG Group
    Patients who underwent laparoscopic anatomical liver resection guided by transportal (portal vein) injection of ICG.

Primary Outcome Measure

Recurrence-Free Survival (RFS) [ Time Frame: Up to 18 months post-surgery (assessing the 18-month RFS rate as a key benchmark) ]

Central Contacts

Find similar trials

Nationwide
Liver cancer trialsOncology trialsGI oncology trialsHepatology trials

Related Studies